Capsid Antibodies to Different Adeno-Associated Virus Serotypes Bind Common Regions
Open accessThe DOI matches its Crossref record; 103 of the 104 references it cites were found in a registry or an index.
Abstract
Interactions between viruses and the host antibody immune response are critical in the development and control of disease, and antibodies are also known to interfere with the efficacy of viral vector-based gene delivery. The adeno-associated viruses (AAVs) being developed as vectors for corrective human gene delivery have shown promise in clinical trials, but preexisting antibodies are detrimental to successful outcomes. However, the antigenic epitopes on AAV capsids remain poorly characterized. Cryo-electron microscopy and three-dimensional image reconstruction were used to define the locations of epitopes to which monoclonal fragment antibodies (Fabs) against AAV1, AAV2, AAV5, and AAV6 bind. Pseudoatomic modeling showed that, in each serotype, Fabs bound to a limited number of sites near the protrusions surrounding the 3-fold axes of the T=1 icosahedral capsids. For the closely related AAV1 and AAV6, a common Fab exhibited substoichiometric binding, with one Fab bound, on average, between two of the three protrusions as a consequence of steric crowding. The other AAV Fabs saturated the capsid and bound to the walls of all 60 protrusions, with the footprint for the AAV5 antibody extending toward the 5-fold axis. The angle of incidence for each bound Fab on the AAVs varied and resulted in significant differences in how much of each viral capsid surface was occluded beyond the Fab footprints. The AAV-antibody interactions showed a common set of footprints that overlapped some known receptor-binding sites and transduction determinants, thus suggesting potential mechanisms for virus neutralization by the antibodies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“VR-VIII is part of an AAV2 antigenic epitope, and the difference is consistent with rAAV2.7m8’s escape from a known AAV2 monoclonal antibody, C37-B.”
From Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2 (2020) · cites this paper as Gurda et al., 2013
The cited source says what the claim attributes to it.
In the citing paper
“This observation is consistent with the positioning of the peptide insert above at the epitope mapped for C37-B to VR-VIII using cryo-EM of the AAV2-C37-B complex (Fig. 8B) (Gurda et al., 2013).”
From Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2 (2020) · cites this paper as Gurda et al., 2013
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The rAAV2.7m8 insertion modified the C37-B antibody binding site (Gurda et al., 2013) creating an escape variant.”
From Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2 (2020) · cites this paper as Gurda et al., 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,828 · cited 7×
“The fit-in-map function in Chimera was used to compare each AAV:Fab cryo-reconstruction to the corresponding map of the AAV:Fab model for quantitative assessment of the Fab docking.”
MethodInfluentialCoot : model-building tools for molecular graphics
Emsley, P., & Cowtan, K. (2004) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444904019158 · Cited by 30,571 · cited 5×
“docked models in the program COOT (75), the absolute scale of each map”
InfluentialFeatures and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 9,984 · cited 5×
“(WAM) model of the 4E4 Fab, the PDBePISA application (84)”
BackgroundMethodInfluentialCryo-electron microscopy of vitrified specimens
Dubochet, J., Adrian, M., Chang, J.-J., Homo, J.-C., Lepault, J., McDowall, A. W., & Schultz, P. (1988) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583500004297 · Cited by 2,389 · cited 1×
“5 l) of AAV:Fab complexes were vitrified using standard rapid freeze-plunging procedures (64, 65).”
MethodManno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490 · cited 1×
“Each AAV serotype has a distinct ability to transduce cells and tissues of different hosts when the same transgene is packaged, indicating that the capsid itself dictates these differences (27, 37).”
BackgroundSummerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406
Self-citationCryo-electron microscopy of viruses
Adrian, M., Dubochet, J., Lepault, J., & McDowall, A. W. (1984) · Nature · doi:10.1038/308032a0 · Cited by 1,342 · cited 1×
“5 l) of AAV:Fab complexes were vitrified using standard rapid freeze-plunging procedures (64, 65).”
Method
Research works printed but not linked: 2
- 18. Chapman MS, Agbandje-McKenna M. 2006. Atomic structures of viral particles, p 107–123 In Kerr JR, Cotmore SF, Bloom ME, Linden RL, Parrish CR. (ed), Parvoviruses. Edward Arnold, Ltd., New York, NY [Google Scholar]
- 19. Agbandje-McKenna M, Chapman MS. 2006. Corrleating structure with function in the viral capsid, p 125–139 In Kerr JR, Cotmore SF, Bloom ME, Linden RM, Parrish CR. (ed), Parvoviruses. Edward Arnold, Ltd., New York, NY [Google Scholar]
Cited by
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
In Silico Reconstruction of the Viral Evolutionary Lineage Yields a Potent Gene Therapy Vector
Zinn, E., Pacouret, S., Khaychuk, V., Turunen, H. T., Carvalho, L. S., Andres-Mateos, E., Shah, S., Shelke, R., Maurer, A. C., Plovie, E., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.07.019 · Cited by 310
“(Mingozzi et al., 2007) Mouse B-cell epitopes of defined AAV2 antibody SADNNNS plus RGNRQ for C37B Fab (Gurda et al., 2013).”
BackgroundCapsid modifications for targeting and improving the efficacy of AAV vectors
Büning, H., & Srivastava, A. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.008 · Cited by 260
“Topological prominent capsid surface structures are pores or “channel-like-structures” at each fivefold, depressions at each twofold, and three protrusions surrounding each threefold axis of symmetry.(37) The pores allow exchange between the capsid interior and the outside.”
BackgroundBucher, K., Rodríguez-Bocanegra, E., Dauletbekov, D., & Fischer, M. D. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100915 · Cited by 242
Tse, L. V., Klinc, K. A., Madigan, V. J., Castellanos Rivera, R. M., Wells, L. F., Havlik, L. P., Smith, J. K., Agbandje-McKenna, M., & Asokan, A. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704766114 · Cited by 210
“Here we tested this hypothesis using AAV1 as a template, which we chose because of the availability of extensive structural information pertaining to this capsid complexed with different mAbs and its cognate glycan receptor, sialic acid (SA) (9, 10, 16).”
BackgroundMethodSelf-citationTwenty-Five Years of Structural Parvovirology
Mietzsch, M., Pénzes, J. J., & Agbandje-McKenna, M. (2019) · Viruses · doi:10.3390/v11040362 · Cited by 197
“[115] AAV2 A20 2012 2/5-fold wall Yes 8.”
Self-citationInfluence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction
Fitzpatrick, Z., Leborgne, C., Barbon, E., Masat, E., Ronzitti, G., van Wittenberghe, L., Vignaud, A., Collaud, F., Charles, S., Simon Sola, M., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.02.003 · Cited by 192
Comparative Analysis of Adeno-Associated Virus Capsid Stability and Dynamics
Rayaprolu, V., Kruse, S., Kant, R., Venkatakrishnan, B., Movahed, N., Brooke, D., Lins, B., Bennett, A., Potter, T., McKenna, R., et al. (2013) · Journal of Virology · doi:10.1128/jvi.01415-13 · Cited by 160
“Structural studies of AAV1 and AAV2 with neutralizing antibodies also map antigenic epitopes to the 3-fold region (105).”
BackgroundSelf-citationRumachik, N. G., Malaker, S. A., Poweleit, N., Maynard, L. H., Adams, C. M., Leib, R. D., Cirolia, G., Thomas, D., Stamnes, S., Holt, K., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.018 · Cited by 154
Rumachik, N. G., Malaker, S. A., Poweleit, N., Maynard, L. H., Adams, C. M., Leib, R. D., Cirolia, G., Thomas, D., Stamnes, S., Holt, K., et al. (2019) · doi:10.1101/640169 · Cited by 156
Adeno-associated virus (AAV) cell entry: structural insights
Meyer, N. L., & Chapman, M. S. (2022) · Trends in Microbiology · doi:10.1016/j.tim.2021.09.005 · Cited by 144
Tseng, Y.-S., & Agbandje-McKenna, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00009 · Cited by 134
“F4 (3C5), based on a structure reconstructed to ~16 Å resolution (36).”
BackgroundMethodInfluentialSelf-citationAdeno-associated Virus Vectors in Gene Therapy
Mary, B., Khan, N., Arumugam, S., Saxena, H., Kumar, M., Manimaran, P., Chattopadhyay, S., & Jayandharan, G. R. (2018) · Springer eBooks · doi:10.1007/978-981-13-0481-1_2 · Cited by 127
Adeno-associated virus: fit to serve
Zinn, E., & Vandenberghe, L. H. (2014) · Current Opinion in Virology · doi:10.1016/j.coviro.2014.07.008 · Cited by 122
Adeno-Associated Virus (AAV) Versus Immune Response
Rabinowitz, J., Chan, Y. K., & Samulski, R. J. (2019) · Viruses · doi:10.3390/v11020102 · Cited by 122
“However, for AAV5 the antigenic footprint flanks the 2/5-fold wall [49,50].”
BackgroundSelf-citationAdeno-Associated Virus Structural Biology as a Tool in Vector Development
Drouin, L. M., & Agbandje-McKenna, M. (2013) · Future Virology · doi:10.2217/fvl.13.112 · Cited by 114
Self-citationTordo, J., O’Leary, C., Antunes, A. S. L. M., Palomar, N., Aldrin-Kirk, P., Basche, M., Bennett, A., D’Souza, Z., Gleitz, H., Godwin, A., et al. (2018) · Brain · doi:10.1093/brain/awy126 · Cited by 113
“1C and E–G), which are involved in receptor binding and determine the antigenic properties of AAV capsids (Gurda et al., 2013; Tseng et al., 2015).”
BackgroundSelf-citationStrategy to detect pre-existing immunity to AAV gene therapy
Falese, L., Sandza, K., Yates, B., Triffault, S., Gangar, S., Long, B., Tsuruda, L., Carter, B., Vettermann, C., Zoog, S. J., et al. (2017) · Gene Therapy · doi:10.1038/gt.2017.95 · Cited by 101
Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site
Huang, L.-Y., Patel, A., Ng, R., Miller, E. B., Halder, S., McKenna, R., Asokan, A., & Agbandje-McKenna, M. (2016) · Journal of Virology · doi:10.1128/jvi.00161-16 · Cited by 101
“The antigenic structures of AAV1, AAV2, AAV5, AAV6, and AAV8 have been characterized by cryo-electron microscopy and image reconstruction (41, 58, 73, 74).”
BackgroundSelf-citationAdeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0052-2014 · Cited by 87
“The three-fold axis is characterized by prominent spike-like protrusions and contains the known receptor binding sites (12, 13) as well as many of the identified antibody recognition sites (14, 15).”
BackgroundSelf-citationLi, X., Salvia, S. L., Liang, Y., Adamiak, M., Kohlbrenner, E., Jeong, D., Chepurko, E., Ceholski, D. K., López-Gordo, E., Yoon, S., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.063759 · Cited by 97
Rossi, A., Dupaty, L., Aillot, L., Zhang, L., Gallien, C., Hallek, M., Odenthal, M., Adriouch, S., Salvetti, A., & Büning, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-40071-1 · Cited by 85
AAV Ancestral Reconstruction Library Enables Selection of Broadly Infectious Viral Variants
Santiago-Ortiz, J., Ojala, D. S., Westesson, O., Weinstein, J. R., Wong, S. Y., Steinsapir, A., Kumar, S., Holmes, I., & Schaffer, D. V. (2015) · Gene Therapy · doi:10.1038/gt.2015.74 · Cited by 83
“53 Given that AAV1 is a descendant of the node 27 ancestral reconstruction, we aligned known AAV1 epitopes 54 with the ancestral reconstruction sequence.”
MethodStructure of the gene therapy vector, adeno-associated virus with its cell receptor, AAVR
Meyer, N. L., Hu, G., Davulcu, O., Xie, Q., Noble, A. J., Yoshioka, C., Gingerich, D. S., Trzynka, A., David, L., Stagg, S. M., et al. (2019) · eLife · doi:10.7554/elife.44707 · Cited by 83
Adeno-associated virus (AAV) vectors: Rational design strategies for capsid engineering
Lee, E. J., Guenther, C. M., & Suh, J. (2018) · Current Opinion in Biomedical Engineering · doi:10.1016/j.cobme.2018.09.004 · Cited by 83
“The β-strands connected by variable surface loops produce capsid surface topological variations – much of which can be found around the capsid’s three-fold spikes (a region frequently implicated in receptor binding and antibody recognition) [15,16].”
BackgroundPrimate optogenetics: Progress and prognosis
El-Shamayleh, Y., & Horwitz, G. D. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902284116 · Cited by 87
Thwaite, R., Pagès, G., Chillón, M., & Bosch, A. (2015) · Gene Therapy · doi:10.1038/gt.2014.103 · Cited by 76
Marsic, D., Govindasamy, L., Currlin, S., Markusic, D. M., Tseng, Y.-S., Herzog, R. W., Agbandje-McKenna, M., & Zolotukhin, S. (2014) · Molecular Therapy · doi:10.1038/mt.2014.139 · Cited by 72
Self-citationAdeno-Associated Viruses (AAV) and Host Immunity – A Race Between the Hare and the Hedgehog
Rapti, K., & Grimm, D. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.753467 · Cited by 79
Albright, B. H., Simon, K. E., Pillai, M., Devlin, G. W., & Asokan, A. (2019) · Journal of Virology · doi:10.1128/jvi.00332-19 · Cited by 72
“Furthermore, these surfaceexposed loops determine the topology of the capsid surface and have a profound effect on virus-host interactions, dictating receptor usage, antigenicity, tissue tropism, and species specificity (8, 9).”
BackgroundTseng, Y.-S., Gurda, B. L., Chipman, P., McKenna, R., Afione, S., Chiorini, J. A., Muzyczka, N., Olson, N. H., Baker, T. S., Kleinschmidt, J., et al. (2015) · Journal of Virology · doi:10.1128/jvi.02710-14 · Cited by 70
“These regions are close to or overlap epitopes previously reported for antibodies against AAV2, AAV6, and AAV8, as well as two MAbs, 4E4 and 5H7, against AAV1, and MAb 3C5 against AAV5 (36, 37, 45).”
BackgroundMethodInfluentialSelf-citationLópez-Gordo, E., Chamberlain, K., Riyad, J. M., Kohlbrenner, E., & Weber, T. (2024) · Viruses · doi:10.3390/v16030442 · Cited by 70
Structure of neurotropic adeno-associated virus AAVrh.8
Halder, S., Van Vliet, K., Smith, J. K., Duong, T. T. P., McKenna, R., Wilson, J. M., & Agbandje-McKenna, M. (2015) · Journal of Structural Biology · doi:10.1016/j.jsb.2015.08.017 · Cited by 64
“Mutagenesis studies have identified residues N498, W503, and P504, and Q590 in VR-V and VR-VIII, respectively, to affect liver and muscle-specific transduction in AAV9 (Pulicherla et al., 2011) and all these residues except P504 are conserved in AAVrh.8, AAV8, and AAV2 (T504 in AAVrh.8; T506 in AAV8 and T503 in AAV2).”
BackgroundMethodInfluentialSelf-citationStrategies to circumvent humoral immunity to adeno-associated viral vectors
Tse, L. V., Moller-Tank, S., & Asokan, A. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1035645 · Cited by 61
“These shared regions are present within the threefold protrusion and the two/fivefold wall on AAV1, 5 and 6 [47,52,53].”
BackgroundLiu, A. P., Patel, S. K., Xing, T., Yan, Y., Wang, S., & Li, N. (2020) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2020.113481 · Cited by 57
Adeno-Associated Virus (AAV) Gene Delivery: Dissecting Molecular Interactions upon Cell Entry
Large, E. E., Silveria, M., Zane, G. M., Weerakoon, O., & Chapman, M. S. (2021) · Viruses · doi:10.3390/v13071336 · Cited by 59
“Residue differences between Anc80, predicted AAV2 ancestral nodes, and AAV2 were superimposed on predicted T cell and antibody epitopes [84,85].”
BackgroundDrouin, L. M., Lins, B., Janssen, M., Bennett, A., Chipman, P., McKenna, R., Chen, W., Muzyczka, N., Cardone, G., Baker, T. S., et al. (2016) · Journal of Virology · doi:10.1128/jvi.00575-16 · Cited by 52
Self-citationStructure of an Enteric Pathogen, Bovine Parvovirus
Kailasan, S., Halder, S., Gurda, B. L., Bladek, H., Chipman, P. R., McKENNA, R. V., Brown, K. E., & Agbandje‐McKenna, M. (2014) · Journal of Virology · doi:10.1128/jvi.03157-14 · Cited by 56
Self-citationIdentification of an adeno-associated virus binding epitope for AVB sepharose affinity resin
Wang, Q., Lock, M., Prongay, A. J., Alvira, M. R., Petkov, B., & Wilson, J. M. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.40 · Cited by 50
Structural Insights into Human Bocaparvoviruses
Mietzsch, M., Kailasan, S., Garrison, J., Ilyas, M., Chipman, P., Kantola, K., Janssen, M. E., Spear, J., Sousa, D., McKenna, R., et al. (2017) · Journal of Virology · doi:10.1128/jvi.00261-17 · Cited by 53
Self-citationNance, M. E., & Duan, D. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.107 · Cited by 51
“37,105,106 High-resolution imaging shows that capsid epitopes tend to localize around the threefold pro-trusions and overlap with key regions involved in receptor recognition and tropism.”
Reid, C. A., Ertel, K. J., & Lipinski, D. M. (2017) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.17-22281 · Cited by 51
“, monoclonal fragment antibodies) as the modifications do not affect the structure of the protrusions near the 3-fold axis (AAV2 epitopes).(42) Supporting this theory, in a previous study we demonstrated that rAAV2/2[QuadYFþTV] was neutralized by serum containing antibodies raised against AAV2.”
ResultLi, C., Wu, S., Albright, B., Hirsch, M., Li, W., Tseng, Y.-S., Agbandje-McKenna, M., McPhee, S., Asokan, A., & Samulski, R. J. (2016) · Molecular Therapy · doi:10.1038/mt.2015.134 · Cited by 48
Self-citationCryo-electron Microscopy of Adeno-associated Virus
Stagg, S. M., Yoshioka, C., Davulcu, O., & Chapman, M. S. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00936 · Cited by 50
Protease-activatable adeno-associated virus vector for gene delivery to damaged heart tissue
Guenther, C. M., Brun, M. J., Bennett, A. D., Ho, M. L., Chen, W., Zhu, B., Lam, M., Yamagami, M., Kwon, S., Bhattacharya, N., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.01.015 · Cited by 46
“The different serological profile of L001 compared to AAV9 is perhaps not too surprising, considering that the 3-fold protrusions where the peptide lock is inserted is known to be a common site for neutralizing antibody binding and recognition, and G453-N457 has been identified as a potential neutralizing antibody epi…”
BackgroundSelf-citationCabanes‐Creus, M., Westhaus, A., Navarro, R. G., Baltazar, G., Zhu, E., Amaya, A. K., Liao, S. H. Y., Scott, S., Sallard, E., Dilworth, K. L., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.004 · Cited by 45
“These VRs interact to form the 3-fold protrusion on the external surface of the capsid, and this region has been shown to be important for AAV antigenic reactivity, sialic acid binding, and HSPG binding (Figures 2A–2C).(47,48)”
BackgroundSelf-citationJose, A., Mietzsch, M., Smith, J. K., Kurian, J., Chipman, P., McKenna, R., Chiorini, J., & Agbandje-McKenna, M. (2019) · Journal of Virology · doi:10.1128/jvi.01394-18 · Cited by 44
“, AAV1-5H7 (9, 30), AAV1-ADK1a (11), AAV2-C37B (9, 25), AAV6-ADK6 (13), and AAV8-ADK8 (10), neutralize the transduction capability of the respective AAV serotype.”
BackgroundInfluentialSelf-citationImage processing for cryogenic transmission electron microscopy of symmetry-mismatched complexes
Huiskonen, J. T. (2018) · Bioscience Reports · doi:10.1042/bsr20170203 · Cited by 44
Structure-guided AAV capsid evolution strategies for enhanced CNS gene delivery
Gonzalez, T. J., Mitchell-Dick, A., Blondel, L. O., Fanous, M. M., Hull, J. A., Oh, D. K., Møller-Tank, S., Rivera, R. M. C., Piedrahita, J. A., & Asokan, A. (2023) · Nature Protocols · doi:10.1038/s41596-023-00875-y · Cited by 42
The structure of AAVrh32.33, a novel gene delivery vector
Mikals, K., Nam, H.-J., Van Vliet, K., Vandenberghe, L. H., Mays, L. E., McKenna, R., Wilson, J. M., & Agbandje-McKenna, M. (2014) · Journal of Structural Biology · doi:10.1016/j.jsb.2014.03.020 · Cited by 41
“…structure variation in the VRs serve as determinants of differential receptor attachment, transduction efficiency, and antigenicity between the AAVs (DiMattia et al., 2012; Govindasamy et al., 2006; Gurda et al., 2012, 2013; McCraw et al., 2012; Nam et al., 2007; Ng et al., 2010; Xie et al., 2011).”
InfluentialSelf-citationMapping Antigenic Epitopes on the Human Bocavirus Capsid
Kailasan, S., Garrison, J., Ilyas, M., Chipman, P., McKenna, R., Kantola, K., Söderlund-Venermo, M., Kučinskaitė-Kodzė, I., Žvirblienė, A., & Agbandje-McKenna, M. (2016) · Journal of Virology · doi:10.1128/jvi.02998-15 · Cited by 38
“Of the overlapping parvovirus antigenic regions in B19, the epitope comprising residues 314 to 330 within VR-IV on the 3-fold protrusion is similar to the C37-B neutralizing antibody epitope in AAV2 that interferes with receptor binding (62, 70, 71).”
BackgroundSelf-citationAn Emerging Adeno-Associated Viral Vector Pipeline for Cardiac Gene Therapy
Asokan, A., & Samulski, R. J. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.2515 · Cited by 38
“The recent mapping of surface-exposed antigenic epitopes using cryo-EM (Gurda et al., 2012, 2013; Harbison et al., 2012; Lerch et al., 2012) is likely to enable structure-driven genetic manipulation of different cardiotropic AAV serotypes to generate novel, neutralizing antibody escape variants…”
BackgroundSelf-citationGiles, A. R., Govindasamy, L., Somanathan, S., & Wilson, J. M. (2018) · Journal of Virology · doi:10.1128/jvi.01011-18 · Cited by 40
“To date, all novel mapped AAV mAbs are specific for an individual serotype and cross-react only with closely related serotypes (for example, 5H7 binding to both AAV1 and AAV6); no previously isolated neutralizing AAV mAbs recapitulate the broader responses commonly seen following AAV infection (34).”
Xie, Q., Spear, J. M., Noble, A. J., Sousa, D. R., Meyer, N. L., Davulcu, O., Zhang, F., Linhardt, R. J., Stagg, S. M., & Chapman, M. S. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.02.004 · Cited by 37
Emmanuel, S. N., Smith, J. K., Hsi, J., Tseng, Y.-S., Kaplan, M., Mietzsch, M., Chipman, P. R., Asokan, A., McKenna, R., & Agbandje‐McKenna, M. (2021) · Journal of Virology · doi:10.1128/jvi.01251-21 · Cited by 36
“Thirteen human and nonhuman primate serotypes (AAV1-13) have been described, each with various transduction efficiency in different host tissues (11).”
InfluentialSelf-citationCorneal Regeneration Using Gene Therapy Approaches
Sarkar, S., Panikker, P., D’Souza, S., Shetty, R., Mohan, R. R., & Ghosh, A. (2023) · Cells · doi:10.3390/cells12091280 · Cited by 40
Structure comparison of the chimeric AAV2.7m8 vector with parental AAV2
Bennett, A., Keravala, A., Makal, V., Kurian, J., Belbellaa, B., Aeran, R., Tseng, Y.-S., Sousa, D., Spear, J., Gasmi, M., et al. (2020) · Journal of Structural Biology · doi:10.1016/j.jsb.2019.107433 · Cited by 33
“The wall of the 2-fold depression is formed by VR-VI, the 2/5-fold wall is formed by VR-I, VR-III, and VR-IX, the top of the 5-fold channel is formed by VR-II, and the protrusions surrounding the 3-fold axis is composed of VR-IV, J Struct Biol.”
BackgroundInfluentialSelf-citationEmmanuel, S. N., Mietzsch, M., Tseng, Y.-S., Smith, J. K., & Agbandje‐McKenna, M. (2021) · Viral Immunology · doi:10.1089/vim.2020.0022 · Cited by 33
“(51) 5H7 23 V, VIII 494, 496–499, 582, 583, 588–595, 597 Gurda et al.”
BackgroundInfluentialSelf-citationStrategies to improve safety profile of AAV vectors
Suoranta, T., Laham-Karam, N., & Ylä‐Herttuala, S. (2022) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2022.1054069 · Cited by 33
Hakim, C. H., Yue, Y., Shin, J., Williams, R. R., Zhang, K., Smith, B. F., & Duan, D. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2014.2 · Cited by 33
López-Astacio, R. A., Adu, O. F., Lee, H., Hafenstein, S. L., & Parrish, C. R. (2023) · Journal of Virology · doi:10.1128/jvi.00161-23 · Cited by 30
Self-citationSilveria, M., Large, E. E., Zane, G. M., White, T., & Chapman, M. S. (2020) · Viruses · doi:10.3390/v12111326 · Cited by 32
Chai, Z., Sun, J., Rigsbee, K. M., Wang, M., Samulski, R. J., & Li, C. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.005 · Cited by 27
Self-citationKellish, P. C., Marsic, D., Crosson, S. M., Choudhury, S., Scalabrino, M. L., Strang, C. E., Hill, J. L., McCullough, K. T., Peterson, J. J., Fajardo, D. S., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.10.001 · Cited by 28
“14,15 A comparison of VP3 structures of different naturally occurring AAVs led to the identi fi cation of nine variable regions (VRs), named VR-I through VR-IX.”
Creating an arsenal of Adeno-associated virus (AAV) gene delivery stealth vehicles
Smith, J. K., & Agbandje‐McKenna, M. (2018) · PLoS Pathogens · doi:10.1371/journal.ppat.1006929 · Cited by 26
Self-citationAtomic Resolution Structures of Human Bufaviruses Determined by Cryo-Electron Microscopy
Ilyas, M., Mietzsch, M., Kailasan, S., Väisänen, E., Luo, M., Chipman, P., Smith, J., Kurian, J., Sousa, D., McKenna, R., et al. (2018) · Viruses · doi:10.3390/v10010022 · Cited by 25
“Viruses 2018, 10, 22 13 of 18 Significantly, both AAV2 and B19 utilize amino acids located on the loops forming the 3-fold protrusions to interact with cell surface glycan recepto s [48–50].”
BackgroundInfluentialSelf-citationSeek and destroy: targeted adeno-associated viruses for gene delivery to hepatocellular carcinoma
Dhungel, B. P., Jayachandran, A., Layton, C. J., & Steel, J. C. (2017) · Drug Delivery · doi:10.1080/10717544.2016.1247926 · Cited by 24
“Even though the most frequent of these antibodies are directed against AAV serotype 2, cross-reactivity between wide ranges of serotypes due to conserved amino acid sequences in the viral capsid has been reported (Calcedo & Wilson, 2013; Gurda et al., 2013).”
BackgroundGene Therapy for Coagulation Disorders
Swystun, L. L., & Lillicrap, D. (2016) · Circulation Research · doi:10.1161/circresaha.115.307015 · Cited by 26
“Unfortunately, even with the generation of novel AAV capsids, the issue of cross reactivity of the immune response may still be an obstacle to avoiding the subsequent cellular immune attack.(73) With the development of a cytotoxic T cell response to AAV capsid peptides, transduced liver cells are killed and the transg…”
Lotfinia, M., Abdollahpour‐Alitappeh, M., Hatami, B., Zali, M. R., & Karimipoor, M. (2019) · Clinical and Experimental Medicine · doi:10.1007/s10238-019-00557-8 · Cited by 28
Goetschius, D. J., Hartmann, S. R., Organtini, L. J., Callaway, H., Huang, K., Bator, C. M., Ashley, R. E., Makhov, A. M., Conway, J. F., Parrish, C. R., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025452118 · Cited by 24
“Incubating with excess Fab molecules to occupy all icosahedrally equivalent sites on capsids has long been the preferred cryo-EM structural approach since this allows icosahedral symmetry averaging to be imposed during the reconstruction process for maximizing resolution (18, 25, 26).”
Self-citationEngineering novel adeno-associated viruses (AAVs) for improved delivery in the nervous system
Carneiro, A. D., & Schaffer, D. V. (2024) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2024.102532 · Cited by 22
Engineered adeno-associated virus 3 vector with reduced reactivity to serum antibodies
Ito, M., Takino, N., Nomura, T., Kan, A., & Muramatsu, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-88614-9 · Cited by 23
Li, Y., Li, J., Liu, Y., Shi, Z., Liu, H., Wei, Y., & Yang, L. (2019) · Gene Therapy · doi:10.1038/s41434-019-0081-8 · Cited by 21
Stone, D., Kenkel, E. J., Loprieno, M. A., Tanaka, M., Feelixge, H. S. D. S., Kumar, A. J., Stensland, L., Obenza, W., Wangari, S., Ahrens, C. Y., et al. (2021) · Human Gene Therapy · doi:10.1089/hum.2020.113 · Cited by 21
“A subset of these are NAbs, which block viral infection by binding epitopes critical for cellular entry.(17,18) Broadly cross-reactive antibody responses to multiple AAV serotypes can be induced after a single natural infection with AAV.”
BackgroundImmunogenicity of Novel AAV Capsids for Retinal Gene Therapy
Gehrke, M., Diedrichs‐Möhring, M., Bogedein, J., Büning, H., Michalakis, S., & Wildner, G. (2022) · Cells · doi:10.3390/cells11121881 · Cited by 20
“oclonal antibodies A20 [28,29] and C37-B [28,30] are highlighted in green and cyan, respectively.”
BackgroundXiang, Y. S., & Hao, G. G. (2023) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-023-00518-5 · Cited by 21
Mietzsch, M., Hull, J. A., Makal, V., Ybargollin, A. J., Yu, J. C., McKissock, K., Bennett, A. D., Pénzes, J. J., Lins, B., Yu, Q., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00335-22 · Cited by 19
Self-citationStructural and Biophysical Analysis of Adeno-Associated Virus Serotype 2 Capsid Assembly Variants
Bennett, A. D., Gargas, J., Kansol, A., Lewis, J., Hsi, J., Hull, J. A., Mietzsch, M., Tartaglia, L. J., Muzyczka, N., Bhattacharya, N., et al. (2023) · Journal of Virology · doi:10.1128/jvi.01772-22 · Cited by 21
Self-citationMacdonald, J., Marx, J., & Büning, H. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.169 · Cited by 18
Large, E. E., & Chapman, M. S. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1116896 · Cited by 18
“Neutralizing anti-AAV2 C37B binds to the 3-fold spike, proximal to the heparin site (Figure 5E; Gurda et al., 2013), possibly accounting for the observed inhibition of cell attachment (Wobus et al.”
BackgroundInfluentialDevelopment of a Bispecific Antibody-Based Platform for Retargeting of Capsid Modified AAV Vectors
Kuklik, J., Michelfelder, S., Schiele, F., Kreuz, S., Lamla, T., Müller, P., & Park, J. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158355 · Cited by 18
“As previously described, the position surrounding 587 is located within the variable surface region of loop eight of the AAV2 capsid and tolerates capsid modifications [11,42,45,46].”
BackgroundTong, J. G., Evans, A. C., Ho, M. L., Guenther, C. M., Brun, M., Judd, J., Wu, E., & Suh, J. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.034 · Cited by 17
Structural characterization of a bat Adeno-associated virus capsid
Mietzsch, M., Li, Y., Kurian, J. J., Smith, J. K., Chipman, P. R., McKENNA, R. V., Yang, L., & Agbandje‐McKenna, M. (2020) · Journal of Structural Biology · doi:10.1016/j.jsb.2020.107547 · Cited by 18
Self-citationMietzsch, M., Hsi, J., Nelson, A. R., Khandekar, N., Huang, A.-M., Smith, N. J. C., Zachary, J., Potts, L., Farrar, M. A., Chipman, P. R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59088-4 · Cited by 17
Self-citationImmune responses in retinal gene therapy: challenges, mechanisms, and future strategies
Ma, Y., & Shen, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1664968 · Cited by 15
Comparative structural, biophysical, and receptor binding study of true type and wild type AAV2
Bennett, A. D., Hull, J. A., Jolinon, N., Tordo, J., Moss, K., Binns, E., Mietzsch, M., Hagemann, C., Linden, R. M., Serio, A., et al. (2021) · Journal of Structural Biology · doi:10.1016/j.jsb.2021.107795 · Cited by 14
Self-citationRationally engineered novel AAV capsids for intra-articular gene delivery
Li, W., Feng, S. L., Herrschaft, L., Samulski, R. J., & Li, C. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101211 · Cited by 12
“51 Gurda et al. re-ported that VRIV in AAV9 is involved in Nab binding, receptor binding, and transduction ef fi ciency; 52 they also identi fi ed that VRVIII plays a role in Nab escape and transduction in AAV2 and AAV8.”
BackgroundSelf-citationIkeda, T., Yamaguchi, Y., Oyama, H., Matsushita, A., Tsunaka, Y., Fukuhara, M., Torisu, T., & Uchiyama, S. (2024) · Viruses · doi:10.3390/v16040585 · Cited by 12
Fluorescence Microscopy in Adeno-Associated Virus Research
Golm, S. K., Hübner, W., & Müller, K. M. (2023) · Viruses · doi:10.3390/v15051174 · Cited by 13
“AAV5 3C5 2/5-fold wall siteA: 254–261, 374, 375, 483, 485–492, 494, 496, 499, 500, 501 siteB: 246, 530, 532–538, 653, 654, 656, 657, 704–708 [74]”
InfluentialEmerging Concepts in Vector Development for Glial Gene Therapy: Implications for Leukodystrophies
von Jonquières, G., Rae, C. D., & Housley, G. D. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.661857 · Cited by 12
“These include depressions at each twofold, marked protrusions surrounding the threefold axis and pores and canyons at each fivefold (Xie et al., 2002; DiMattia et al., 2012; Gurda et al., 2013; Zinn et al., 2015).”
BackgroundIroanya, G. I., Subramanyam, P. N., Wells, K. D., & Green, J. A. (2025) · Human Gene Therapy · doi:10.1177/10430342251378524 · Cited by 11
“15,25,47 We will adhere to these de fi nitions throughout the remainder of this article.”
InfluentialThe amazing AAV capsids: Into the structure-verse
Hsi, J., Mietzsch, M., & McKENNA, R. V. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101629 · Cited by 12
Self-citationHeldt, C. L. (2019) · Journal of Chromatography B · doi:10.1016/j.jchromb.2019.06.011 · Cited by 10
Adachi, K., Dissen, G. A., Lomniczi, A., Xie, Q., Ojeda, S. R., & Nakai, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-66596-4 · Cited by 10
Planet of the AAVs: The Spinal Cord Injury Episode
Štěpánková, K., Jendelová, P., & Urdzíková, L. M. (2021) · Biomedicines · doi:10.3390/biomedicines9060613 · Cited by 10
“Different serotypes are defined by distinct capsid protein motifs, determined by different neutralizing antibodies [49].”
BackgroundZarei, M., Wang, P., Jonveaux, J., Haller, F. M., Gu, B., Koulov, A. V., & Jahn, M. (2021) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.9247 · Cited by 9
Surface Modulatable Nanocapsids for Targeting and Tracking Toward Nanotheranostic Delivery
Stark, M., & Cheng, R. H. (2016) · Pharmaceutical Patent Analyst · doi:10.4155/ppa-2016-0021 · Cited by 9
Characterization of the GBoV1 Capsid and Its Antibody Interactions
Yu, J. C., Mietzsch, M., Singh, A., Ybargollin, A. J., Kailasan, S., Chipman, P. R., Bhattacharya, N., Fakhiri, J., Grimm, D., Kapoor, A., et al. (2021) · Viruses · doi:10.3390/v13020330 · Cited by 8
Self-citationGiles, A. R., Calcedo, R., Tretiakova, A. P., & Wilson, J. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01135 · Cited by 8
Structures and functions of the limited natural polyclonal antibody response to parvovirus infection
Adu, O. F., Lee, H., Früh, S. P., Schoenle, M. V., Weichert, W. S., Flyak, A. I., Hafenstein, S. L., & Parrish, C. R. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2423460122 · Cited by 7
Self-citation
Metadata
- Authors
- Gurda, B. L., DiMattia, M. A., Miller, E. B., Bennett, A., McKenna, R., Weichert, W. S., Nelson, C. D., Chen, W.-J., Muzyczka, N., Olson, N. H., Sinkovits, R. S., Chiorini, J. A., Zolotutkhin, S., Kozyreva, O. G., Samulski, R. J., Baker, T. S., Parrish, C. R., & Agbandje-McKenna, M.
- Affiliations
- University of Florida (US)
- Cornell University (US)
- University of California San Diego (US)
- National Institutes of Health (US)
- University of North Carolina at Chapel Hill (US)
- Deptartment of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida, USA
- ORCID
- Venue
- Journal of Virology
- Publisher
- American Society for Microbiology
- Published
- 2013-08-15
- Volume
- 87
- Issue
- 16
- Pages
- 9111-9124
- ISSN
- 0022-538X (ISSN-L)
- 1098-5514
- PMC
- PMC3754064
- OpenAlex
- W2171084404
- Cited by
- 127
- References
- 104
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 6 · 2023: 9 · 2022: 5 · 2021: 15 · 2020: 14 · 2019: 15 · 2018: 13 · 2017: 8 · 2016: 5 · 2015: 9 · 2014: 9 · 2013: 4
- FWCI
- 5.97
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Journal of Virology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- UNC Libraries
- Funders
- National Institutes of Health (4r37gm033050-27)
- University of California, San Diego
- National Heart, Lung, and Blood Institute (P01HL112761)
- National Institute of General Medical Sciences (R37GM-033050, R37 GM-33050, R01GM082946)
- National Institute of Allergy and Infectious Diseases (R01AI072176, R21AI072341)
- National Center for Research Resources (S10RR020016)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Keywords
- adeno-associated virus, AAV capsid, antibody epitopes, AAV serotypes, AAV1, AAV2, AAV5, AAV6, steric crowding, virus neutralization, gene therapy vectors, receptor binding sites
- MeSH terms
- Dependovirus, Antibodies, Monoclonal, Antibodies, Viral, Epitopes, Binding Sites, Capsid, Humans, Models, Molecular, Protein Binding, Cryoelectron Microscopy, Imaging, Three-Dimensional, Macromolecular Substances
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.